These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 16141246)
1. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. Elkord E; Williams PE; Kynaston H; Rowbottom AW Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246 [TBL] [Abstract][Full Text] [Related]
2. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178 [TBL] [Abstract][Full Text] [Related]
3. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353 [TBL] [Abstract][Full Text] [Related]
4. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. Elkord E; Rowbottom AW; Kynaston H; Williams PE Clin Immunol; 2006 Jul; 120(1):91-8. PubMed ID: 16458609 [TBL] [Abstract][Full Text] [Related]
5. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494 [TBL] [Abstract][Full Text] [Related]
6. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387 [TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539 [TBL] [Abstract][Full Text] [Related]
8. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739 [TBL] [Abstract][Full Text] [Related]
9. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation. Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J Transplantation; 2009 Feb; 87(4):467-72. PubMed ID: 19307781 [TBL] [Abstract][Full Text] [Related]
10. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476 [TBL] [Abstract][Full Text] [Related]
11. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Scheibenbogen C; Lee KH; Mayer S; Stevanovic S; Moebius U; Herr W; Rammensee HG; Keilholz U Clin Cancer Res; 1997 Feb; 3(2):221-6. PubMed ID: 9815676 [TBL] [Abstract][Full Text] [Related]
12. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Bae J; Martinson JA; Klingemann HG Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939 [TBL] [Abstract][Full Text] [Related]
14. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648 [TBL] [Abstract][Full Text] [Related]
15. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216 [TBL] [Abstract][Full Text] [Related]
16. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. McNeel DG; Nguyen LD; Ellis WJ; Higano CS; Lange PH; Disis ML Prostate; 2001 May; 47(3):222-9. PubMed ID: 11351352 [TBL] [Abstract][Full Text] [Related]
17. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083 [TBL] [Abstract][Full Text] [Related]
18. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients. Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794 [TBL] [Abstract][Full Text] [Related]
19. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Berlyn KA; Schultes B; Leveugle B; Noujaim AA; Alexander RB; Mann DL Clin Immunol; 2001 Dec; 101(3):276-83. PubMed ID: 11726219 [TBL] [Abstract][Full Text] [Related]
20. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols. Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]